For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FUR865. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by independent medical education grants from AstraZeneca and Jazz Pharmaceuticals.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Taofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Betta Pharmaceuticals Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GenCART; Gilead Sciences, Inc.; GlaxoSmithKline; Heat Biologics Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; OncoHost; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Amgen Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Cardiff Oncology, Inc.; Cyclacel Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Puma Biotechnology, Inc; Turning Point Therapeutics, Inc.; and Y-mAbs Therapeutics, Inc.
Faculty/Planner
Anne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.
Grant/Research Support from AbbVie, Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.
Faculty/Planner
Jared Weiss, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; EMD Serono, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Genmab A/S.; Gilead Sciences, Inc.; Jounce Therapeutics, Inc.; Lilly; Nanobiotix; PDS Biotechnology; Pfizer; and Sanofi.
Grant/Research Support from G1 Therapeutics, Inc.; Inspirna, Inc.; and Lilly.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Grzegorz (Greg) Nowakowski, MD - Taking the Turn to Treatment Innovation in DLBCL: Real-World Insight on Integrating Antibodies and Cellular Therapy Into Patient Care
Biree Andemariam, MD - The Evolution of Sickle Cell Disease: Current Advances and Future Possibilities
Lorinda Chung, MD, MS - Covering All the Bases in SSc-ILD Care: Expert Strategies for Diagnosis, Treatment, and Managing Comorbidities
Nathan H. Fowler, MD - A Better Blend for Follicular Lymphoma: How Targeted, Epigenetic, and Immune Therapies Are Changing Patient Care
Neal K. Lakdawala, MD - Making New Strides in Hypertrophic Cardiomyopathy: The Latest Guidelines, Science, and Strategies for Early Diagnosis and Tailored Treatment
Stephen R. Broderick, MD, MPHS/Heather A. Wakelee, MD - Has Immunotherapy Brought Us to an Inflection Point in the Multimodal Management of Stage I-III NSCLC? Dissecting the Data and Instituting Multi
John C. Byrd, MD - Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety Management
Jennifer Wargo, MD, MMSc - Leveraging Neoadjuvant and Adjuvant Immunotherapy to Break Through the Outcomes Plateau, Prevent Recurrences, and Improve Curability in Early-Stage Cancers
David R. Jones, MD - Adjuvant EGFR-Targeted Therapy as a Game Changer: How to Implement New Standards of Care in Multimodal Management of Stage I-III EGFR-Mutated NSCLC
Javid Moslehi, MD - Improving the Detection and Management of Cardiac Immune-Related Adverse Events in Patients With Cancer Is a Must: Are You Prepared?
Lynette M. Sholl, MD - Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC: Refining and Expanding Best Practices in Advanced and Early-Stage Disease Settings
Jonathan W. Goldman, MD - Translating Science, Transforming Practice, and Making Headway Toward Better Outcomes in SCLC: Immunotherapy Has Changed the Game, but Where Do We Go Next?
Andrew J. Wagner, MD, PhD - Overcoming the Challenges of Diverse TGCT Presentations: Diagnostic and Treatment Principles for the Multidisciplinary Team
Peter A. Kouides, MD - Advancing Treatment of von Willebrand Disease: A Visual Exploration on Personalizing Care With Current and Emerging Management Strategies
Daniel Jacoby, MD - Easing the Burden of Hypertrophic Cardiomyopathy: Progress in Understanding and Addressing Its Pathophysiology
Melissa L. Johnson, MD - Harnessing the Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLC
Srdan Verstovsek, MD, PhD / Ruben A. Mesa, MD, FACP - Understanding the Clinical Spectrum of Myelofibrosis: Expert Perspectives on Molecular Biology, JAK Inhibitors, and Emerging Therapeutics
Anthony R. Mato, MD, MSCE - Interprofessional Perspectives on Safety Management With Targeted Therapy for B-Cell Malignancies
Sagar Lonial, MD, FACP - Breaking Therapeutic Barriers in RRMM: Team-Based Solutions for Integrating Novel Antibody Platforms and Improving Myeloma Care
Ian Pavord, FMedSci - Across the Age Spectrum: Expert Insights on Emerging Uses of Targeted Therapy for the Treatment of Uncontrolled Moderate to Severe Asthma
Create your
podcast in
minutes
It is Free
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
PeerView Internal Medicine CME/CNE/CPE Audio Podcast
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
PeerView Gastroenterology CME/CNE/CPE Audio Podcast